Company Encyclopedia
View More
name
PEGBIO CO-B
02565.HK
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia.
1.267 T
02565.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Softbank China Capital Reaffirms Their Buy Rating on PegBio Co., Ltd. Class H (2565)

    Softbank China Capital has reaffirmed its Buy rating on PegBio Co., Ltd. Class H, setting a price target of HK$101.80. The company's shares closed at HK$63.80. The analyst consensus is Moderate Buy with the same price target. TipRanks offers a 60% discount on its Premium service for investment insights.

    Tip Ranks·
    HK
    02565
    +4.42%
    Tip Ranks·
    HK
    02565
    +4.42%

    Morning Trend | PEGBIO CO-B surges with increased volume, can the short-term bullish sentiment continue?

    PEGBIO CO-B (2565.HK) has recently attracted close attention from market funds, with continuous volume increases and a breakthrough of previous highs, forming a daily MACD golden cross. Technically, the stock price has strongly moved out of an upward channel, with clear support from the MA5 and MA10 moving averages, solidifying the upward trend. Trading volume has significantly increased compared to previous periods, indicating active fund participation in the market. From a sector linkage perspective, innovative drugs and the biopharmaceutical segment are receiving policy support, with clear signs of short-term fund inflows. Currently, the main focus during trading is on the volume-price coordination; if there is continued volume increase and steady price rise in the future, a short-term bullish pattern may continue. However, if there is a continuous breakthrough but trading volume cannot keep up or if the main force shows intentions to distribute at high levels, the stock price may easily fall into fluctuations or even retracement. Strategically, short-term investors can look for low-buy opportunities during intraday pullbacks to the MA5 and MA10; if there is a rapid outflow of large orders, timely profit-taking and exit should be executed. At the same time, attention should be paid to policy and industry catalytic events, adjusting positions dynamically. Overall, short-term fund enthusiasm remains, but subsequent volatility risks should also be monitored, making flexible operations suitable

    Technical Forecast·
    HK
    02565
    +4.42%
    Technical Forecast·
    HK
    02565
    +4.42%

    PEGBIO voluntarily dissolves its subsidiary Shanghai MaiJi to focus on core business and streamline operations

    PEGBIO CO announced that it has applied for the voluntary dissolution of its non-wholly-owned subsidiary, Shanghai MaiJi. The company stated that Shanghai MaiJi is engaged in the research and development of the peptide hormone GLP-2, and the dissolution is aimed at focusing on core business and streamlining operations. After the dissolution, the company will continue to develop its core products in the fields of metabolism and weight loss treatment. Therefore, the dissolution will not have an adverse impact on the overall business operations and financial condition of the company or the group

    AASTOCKS·
    HK
    02565
    +4.42%
    AASTOCKS·
    HK
    02565
    +4.42%

    Understanding the Market | PEGBIO CO-B surged over 20% in the closing session, reaching a new high, recently granting exclusive licensing for diabetes drugs in the Middle East and Africa

    PEGBIO CO-B surged over 20% in late trading, reaching a high of HKD 62.25, setting a new record since its listing. As of the time of publication, it rose 16.51%, trading at HKD 60.3, with a transaction volume of HKD 30.2346 million. In terms of news, PEGBIO recently announced a strategic partnership with PDC FZ-LLC, a leading pharmaceutical research and development institution in the UAE, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's core product Visepegenatide (PB-119) in the Middle East and Africa. This collaboration marks a key step in PEGBIO's global commercialization strategy. It is reported that Visepegenatide (PB-119) is a GLP-1 receptor agonist developed by PEGBIO for weekly subcutaneous injection, used for the treatment of type 2 diabetes and weight management. According to the International Diabetes Federation, the prevalence of diabetes among adults in the Middle East and North Africa is as high as 16.2%, ranking first in the world. This collaboration is expected to accelerate the availability of this innovative therapy, Visepegenatide (PB-119), to many patients in the region with unmet medical needs

    Zhitong·
    HK
    02565
    +4.42%
    Zhitong·
    HK
    02565
    +4.42%

    Hong Kong Stock Movement: PEGBIO CO-B surged 20.08%, with active capital inflow attracting market attention

    PEGBIO CO-B surged 20.08%; Sanofi gained 11.56%, with a transaction volume reaching HKD 2.086 billion; Innovent Biologics rose 8.12%, with a transaction volume reaching HKD 1.842 billion; CanSino Biologics increased 2.43%, with a transaction volume reaching HKD 1.158 billion; BeiGene rose 0.81%, with a market capitalization of HKD 287.3 billion

    HK Stock Movers Tracker·
    HK
    02565
    +4.42%
    HK Stock Movers Tracker·
    HK
    02565
    +4.42%
    © 2025 Longbridge｜Disclaimer